I'm not at all impressed by Titan mgmt, but that being said, I do think a little bit of patience is in order. FDA approval was barely six weeks ago. I'm ok with them not taking the first ROW deal that comes along (if that's some of the hold up), plus what good is a partnership announcement when the approval isn't even in place in other countries yet? besides of course the positive effect on the stock price. I don't think they're too concerned with SP, which is bothersome, but not necessarily the worst thing, assuming they're moving toward the longterm goals - pipeline drugs keep moving along and the partnerships are put in place. Plus, the longer they wait to setup a ROW partnership, the more they'll know with the probuphine sales numbers, which ultimately gives them more leverage. all imo